While treatment with a RIP1 inhibitor after the onset of dermatitis did not restore the lymphoid architecture, this might be due to the late timing of the intervention and it is possible that germline loss of RIP1 kinase activity may restore the lymphoid architecture (Webster et al., 2020). The gene discussed is RIPK1; the disease is skin disorder.